Sensus Healthcare Reports First Quarter 2021 Financial Results Revenues up 83% year-over-year Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (

Sensus Healthcare Reports First Quarter 2021 Financial

Revenues up 83% year-over-year

Conference call begins at 4:30 p.m.

BOCA RATON, Fla. (May 6, 2021) - Sensus Healthcare,

Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective

treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2021.

Highlights from the first quarter of 2021 and recent

weeks include the following (all comparisons are with the first quarter of 2020, unless otherwise indicated):

Management Commentary

"Our business continued to rebound during the

first quarter following the severe impact of the COVID-19 pandemic during most of 2020. Total revenues were significantly higher versus

the prior-year quarter and featured both domestic and overseas sales," said Joe Sardano, chairman and chief executive officer of

Sensus Healthcare. "We are cautiously optimistic that the signs of market recovery will allow continued revenue growth as the year

progresses, noting our historical seasonality during the summer months."

"Currently, the SRT Systems installed at customer

sites are operating with good volumes, likely reflecting not only the safety and efficacy of using SRT to treat non-melanoma skin cancer,

but also a fairer reimbursement environment as of January 1, 2021, as the Centers for Medicare & Medicaid Services revalued our main

procedure and other codes following years of lobbying by Sensus. We believe the higher reimbursement is driving increased interest for

our SRT Systems, including interest in shared revenue programs. Customers and prospective customers alike appear to be satisfied with

the new reimbursement levels and we anticipate this acceptance will be reflected in our revenue during the second half of this year.

"We were delighted to announce the installation

of our 500th system since the formation of Sensus Healthcare a decade ago. The sale was to the Mid-Atlantic Skin Surgery Institute

in Maryland, and was the second purchase of an SRT system by this group. We're looking forward to the installation of the next 500

systems, but in half the time as the first 500," added Mr. Sardano.

"We were pleased to ship another SRT System

to China during the quarter, which came on the heels of the sale of three systems to China during the fourth quarter of 2020. Our new

distribution partner for China and Hong Kong, along with our new vice president of international sales, have developed an extensive network

of prospects, and we expect continued sales there in both the second quarter and the rest of the year. Our preparations for Sculptura

entering the regulatory process in China are ongoing."

"During the first quarter, Sensus was awarded

a patent titled Three-Dimensional Beam Forming X-Ray Source.' This patent contains 31 separate claims and describes the method

of beam splitting and sculpting found in the Sculptura System, our Anisotropic Radiation Therapy with Beam Sculpting capabilities

and Robotic Respiratory Tracking for 17 indications. This new patent covers the delivery of radiation to treat solid tumors of all types.

In addition, there may be opportunity to license this technology for devices other than Sculptura. In the meantime, later this year we

expect our research partners at the University of Pennsylvania to begin supportive studies in breast and other cancers that have been

on pandemic-related hold."

Mr. Sardano added, "We are approaching the launch

of our new aesthetic lasers and completion of the integration of our Sentinel IT Solutions software into the lasers is imminent.

Sentinel provides asset management and HIPAA-compliant patient data and storage capability, and also contains the software necessary to

support shared service models including direct patient billing. We expect the sale of aesthetic lasers will become a meaningful

source of revenue, in particular as we roll out two disruptive rental strategies. These strategies are designed to generate consistent

revenue for Sensus, while providing physician customers with access to multiple lasers. We are also looking at expanding our mobile aesthetic

laser business beyond Florida via strategic transactions.

"I continue to voice my appreciation for our

staff and the way they have maintained a focus on customers and patients throughout the pandemic. I believe we have further strengthened

those relationships and that we are poised to resume meaningful domestic growth with the worst of the pandemic behind us. We look forward

to showcasing our SRT systems along with the Sentinel technology at the Fall Clinical Dermatology Conference during October, which is

expected to be a live show in Las Vegas," Mr. Sardano concluded.

First Quarter Financial Results

Revenues for the first quarter of 2021 were $3.1 million

compared with $1.7 million for the first quarter of 2020. The 83% increase was primarily driven by a higher number of units sold in 2021,

service revenue on installed units, and the impact of COVID-19 on the first quarter of 2020.

Cost of sales for the first quarter of 2021 was $1.5

million compared with $1.0 million for the prior-year quarter. The increase was commensurate with higher sales in the 2021 period.

Gross profit for the first quarter of 2021 was $1.6

million compared with $0.7 million for the first quarter of 2020. Gross margin for the first quarter of 2021 was 51.6% compared with 42.2%

for the prior-year quarter. The increase in gross margin was primarily driven by the higher number of units sold in 2021, service revenue

on installed units and the impact of COVID-19 on the first three months of 2020.

Selling and marketing expense for the first quarter

of 2021 was $1.1 million compared with $1.8 million for the first quarter of 2020. The 40% decrease was primarily attributable to lower

tradeshow expense due to cancellations related to COVID-19, reduced marketing activities, including travel, and reduced headcount.

General and administrative expense for the first quarter

of 2021 was $1.0 million compared with $1.3 million for the first quarter of 2020. The 27% decrease was primarily due to reduced headcount,

partially offset by higher insurance premium costs.

Research and development expense for the first quarter

of 2021 was $0.7 million compared with $1.2 million for the prior-year quarter. The 46% decrease reflected lower spending as the Sculptura

project entered the production phase during 2020.

Net loss for the first quarter of 2021 was $(1.1)

million, or $(0.07) per share, compared with a net loss of $(3.6) million, or $(0.22) per share, for the first quarter of 2020.

Adjusted EBITDA for the first quarter of 2021 was

$(0.8) million compared with $(3.3) million in the first quarter of 2020. Adjusted EBITDA, a non-GAAP financial measure, is defined as

earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between

GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP financial measures are provided.

Cash and cash equivalents were $13.7 million as of

March 31, 2021 compared with $14.9 million as of December 31, 2020. The company had approximately $0.2 million in long-term debt and no

outstanding borrowings under its revolving line of credit at March 31, 2021.

Use of Non-GAAP Financial Information

This press release contains supplemental financial

information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP).

Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of performance. Adjusted EBITDA should

not be considered a substitute for GAAP basis measures nor should it be viewed as a substitute for operating results determined in accordance

with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation,

amortization and stock-compensation expense, provides useful supplemental information that is essential to a proper understanding of the

financial results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation

methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted

EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that

may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in

Conference Call and Webcast

The Company will host an investment community conference

call today beginning at 4:30 p.m. Eastern time, during which management will discuss financial results for the 2021 first quarter, provide

a business update and answer questions. To access the conference call, the dial-in numbers are (888) 390-3967 (U.S. and Canada) or 862-298-0702

(International). Please direct the operator to be connected to the Sensus Healthcare conference call. The call will be webcast live and

can be accessed here or in the Investors section of the Company's website here.

Following the conclusion of the conference call, a

replay will be available and can be accessed by dialing 888-539-4649 (U.S. and Canada) or 754-333-7735 (International). At the prompt,

enter replay code 155558 followed by the # sign. An archived webcast of the call will also be available in the Investors section of the

Company's website for a period of time.

About Sensus Healthcare